|
1
|
Jeannot V, Busser B, Brambilla E, Wislez
M, Robin B, Cadranel J, Coll JL and Hurbin A: The PI3K/AKT pathway
promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by
a deacetylase-dependent mechanism. Int J Cancer. 134:2560–2571.
2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mouradian M, Kikawa KD, Johnson ED, Beck
KL and Pardini RS: Key roles forGRB2-associated-binding protein1,
phosphatidylinositol-3-kinase, cyclooxygenase 2, prostaglandin E2
and transforming growth factor alpha in linoleic
acid-inducedupregulation of lung and breast cancer cell growth.
Prostaglandins Leukot Essent Fatty Acids. 90:105–115.
2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Brückl W, Tufman A and Huber RM: Advanced
non-small cell lung cancer (NSCLC) with activating EGFR mutations:
First-line treatment with afatinib and other EGFR TKIs. Expert Rev
Anticancer Ther. 17:143–155. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500.
2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Engelman JA and Settleman J: Acquired
resistance to tyrosine kinase inhibitors during cancer therapy.
Curr Opin Genet Dev. 18:73–79. 2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Matikas A, Mistriotis D, Georgoulias V and
Kotsakis A: Current and future approaches in the management of
non-small-cell lung cancer patients with resistance to EGFR TKIs.
Clin Lung Cancer. 16:252–261. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jakobsen KR, Demuth C, Sorensen BS and
Nielsen AL: The role of epithelial to mesenchymal transition in
resistance to epidermal growth factor receptor tyrosine kinase
inhibitors in non-small cell lung cancer. Transl Lung Cancer Res.
5:172–182. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhou Q, Yang JJ, Chen ZH, Zhang XC, Yan
HH, Xu CR, Su J, Chen HJ, Tu HY, Zhong WZ, et al: Serial cfDNA
assessment of response and resistance to EGFR-TKI for patients with
EGFR-L858R mutant lung cancer from a prospective clinical trial. J
Hematol Oncol. 9(86)2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gohr K, Hamacher A, Engelke LH and Kassack
MU: Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in
the triple negative breast cancer cell line HCC38. BMC Cancer.
17(711)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Li H, Schmid-Bindert G, Wang D, Zhao Y,
Yang X, Su B and Zhou C: Blocking the PI3K/AKT and MEK/ERK
signaling pathways can overcome gefitinib-resistance in non-small
cell lung cancer cell lines. Adv Med Sci. 56:275–284.
2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Heavey S, O'Byrne KJ and Gately K:
Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.
Cancer Treat Rev. 40:445–456. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kang XH, Xu ZY, Gong YB, Wang L, Wang Z-Q,
Xu L, Cao F and Liao M: Bufalin reverses HGF-induced resistance to
EGFR-TKIs in EGFR mutant lung cancer cells via blockage of
Met/PI3k/Akt pathway and induction of apoptosis. Evid Based
Complement Alternat Med. 2013(243859)2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chen P, Wen X, Wang B, Hou D, Zou H, Yuan
Q, Yang H, Xie J and Huang H: PI3K/Akt inhibitor LY294002
potentiates homoharringtonine antimyeloma activity in myeloma cells
adhered to stromal cells and in SCID mouse xenograft. Ann Hematol.
97:865–875. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Mao Y, Xi L, Li Q, Wang S, Cai Z, Zhang X
and Yu C: Combination of PI3K/Akt Pathway Inhibition and Plk1
Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic
Carcinoma. Transl Oncol. 11:852–863. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wang Y, Kuramitsu Y, Baron B, Kitagawa T,
Tokuda K, Akada J, Maehara SI, Maehara Y and Nakamura K: PI3K
inhibitor LY294002, as opposed to wortmannin, enhances AKT
phosphorylation in gemcitabine-resistant pancreatic cancer cells.
Int J Oncol. 50:606–612. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Russo A, Franchina T, Ricciardi GR, Picone
A, Ferraro G, Zanghì M, Toscano G, Giordano A and Adamo V: A decade
of EGFR inhibition in EGFR-mutated non small cell lung cancer
(NSCLC): Old successes and future perspectives. Oncotarget.
6:26814–26825. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Spanish Lung Cancer Group in
collaboration with Groupe Français de Pneumo-Cancérologie and
Associazione Italiana Oncologia Toracica: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Russo A, Franchina T, Ricciardi GRR,
Smiroldo V, Picciotto M, Zanghì M, Rolfo C and Adamo V: Third
generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and
where are we going. Crit Rev Oncol Hematol. 117:38–47.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Camidge DR, Pao W and Sequist LV: Acquired
resistance to TKIs in solid tumours: Learning from lung cancer. Nat
Rev Clin Oncol. 11:473–481. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kuger S, Graus D, Brendtke R, Günther N,
Katzer A, Lutyj P, Polat B, Chatterjee M, Sukhorukov VL, Flentje M,
et al: Radiosensitization of glioblastoma cell lines by the dual
PI3K and mTOR inhibitor NVP-BEZ235 depends on drug-irradiation
schedule. Transl Oncol. 6:169–179. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Xie X, Tang B, Zhou J, Gao Q and Zhang P:
Inhibition of the PI3K/Akt pathway increases the chemosensitivity
of gastric cancer to vincristine. Oncol Rep. 30:773–782.
2013.PubMed/NCBI View Article : Google Scholar
|
